A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy

What is the purpose of this trial?

This is a pilot study of patients who previously received platinum chemotherapy with recurrent SCLC to evaluate the change in the ratio of intratumoral Teff/Treg cells and clinical benefit of treatment with nivolumab and ipilumumab.



Yale Cancer Center

Start Date: 12/06/2018

End Date: 06/08/2020

Last Updated: 12/07/2018

Study HIC#: 2000023361

Get Involved

For more information about this study, contact:
Kira Pavlik
+1 203-785-6540
kira.pavlik@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image